(VIANEWS) – The NASDAQ ended the session with Arcturus Therapeutics jumping 11.01% to $31.83 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.66% to $15,003.22, after five consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.
Arcturus Therapeutics’s last close was $28.67, 24.05% under its 52-week high of $37.75.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $3.76.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 8.46. Meaning, the purchaser of the share is investing $8.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.66%.
Moving Average
Arcturus Therapeutics’s worth is way above its 50-day moving average of $22.46 and way higher than its 200-day moving average of $25.54.
Yearly Top and Bottom Value
Arcturus Therapeutics’s stock is valued at $31.83 at 02:04 EST, way under its 52-week high of $37.75 and way higher than its 52-week low of $14.21.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Arcturus Therapeutics’s stock is considered to be oversold (<=20).
More news about Arcturus Therapeutics (ARCT).
